Nitwit, most of my shares were purchased in single digits. This Baggie is holding 26500 shares. Lol. This bag holder is proud and wealthy moron lol
Keep trying Nick. Your so transparent. Oh you own 10500 shares. I guess you don't believe in the 10 Commandments do you. Thou shall not lie. lol
Roping off the press like cattle. When will she actually answer some questions? Bernie Sanders only down 8 points. Wow, when a Socialist is closing in on you, your in trouble.
How much debt does the US have? 18 trillion as Obama and his criminals continue to spend like drunken sailors. In addition Maybe if the Greek Gov't would make the Greek people work longer their would not be such problems.Three out of four public sector and Social Security Fund (IKA) pensioners in Greece are opting for early retirement. This situation has caused the country’s pension system to become unsustainable.
On Wednesday, Greek Labor Minister Yiannis Vroutsis presented data to the parliament, explaining that almost 75% of Greek pensioners are trying to secure their early retirement through legal provisions that allow them to stop working before the age of 61.
“In the public sector, 7.91% of pensioners retire between the ages of 26 and 50, 23.64% between 51 and 55, and 43.53% between 56 and 61. In IKA, 4.44% of pensioners retire between the ages of 26 and 50, 12.83% retire between 51 and 55, and 58.61% retire between 56 and 61. Meanwhile, in the so-called healthy funds, 91.6% of people retire before the national retirement age limit,” Vroutsis said.
I don't know about you but I picked up 6% yesterday on my cldx shares. How'd you do? lol
Uh, that came out today on Yahoo at 4:50 PM dip sht . You are going to get crushed you moron lol
Celldex Therapeutics, Inc. CLDX announced that an independent Data Safety and Monitoring Board (DSMB) completed its first pre-specified review of a phase III study (ACT IV) on Rintega (rindopepimut) and recommended the continuation of the study in patients with newly diagnosed glioblastoma.
The randomized, double-blind, placebo controlled study on Rintega plus granulocyte-macrophage colony-stimulating factor (GM-CSF) added to standard-of-care treatment like Merck’s MRK Temodar (temozolomide) is being conducted in patients with newly diagnosed, surgically resected, EGFRvIII-positive glioblastoma.
In the study, 745 patients were enrolled in order to reach the required 374 patients with minimal residual disease needed for analysis of the primary overall survival endpoint. Patients including those with disease that exceed this threshold will be included in a secondary analysis of overall survival as well as analyses of progression-free survival, safety and tolerability and quality of life. Moreover, the timing of the overall survival primary endpoint data is event driven.
The interim analysis, assessing the safety, futility and efficacy of the candidate and being conducted by an independent DSMB, is pre-specified at 50% and 75% of events. With the first interim analysis having been completed, the second is expected to take place in late 2015/early 2016. Final data from the study is expected by the end of 2016.
We remind investors that in late May, Celldex had reported positive results from a phase II exploratory study (ReACT) on Rintega in patients suffering from EGFRvIII-positive, recurrent glioblastoma. We note that Rintega was granted Breakthrough Therapy status for the glioblastoma indication in Feb 2015.
Being the lead candidate in the company’s pipeline, we expect investor focus to remain on updates pertaining to its development.